131 related articles for article (PubMed ID: 33522823)
1. A Peptide-Based Small RNA Delivery System to Suppress Tumor Growth by Remodeling the Tumor Microenvironment.
Zhang R; Tang L; Zhao B; Tian Y; Zhou B; Mu Y; Yang L
Mol Pharm; 2021 Mar; 18(3):1431-1443. PubMed ID: 33522823
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens.
Zhang R; Tang L; Tian Y; Ji X; Hu Q; Zhou B; Zhenyu D; Heng X; Yang L
Biomaterials; 2020 May; 241():119852. PubMed ID: 32120313
[TBL] [Abstract][Full Text] [Related]
3. DP7-C/mir-26a system promotes bone regeneration by remodeling the osteogenic immune microenvironment.
Huang J; Yang Y; Zhu Y; Xiao X; Yalikun K; Jiang X; Yang L; Mu Y
Oral Dis; 2024 Mar; ():. PubMed ID: 38501171
[TBL] [Abstract][Full Text] [Related]
4. Sustained and targeted delivery of siRNA/DP7-C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy.
Zhao B; Zhou B; Shi K; Zhang R; Dong C; Xie D; Tang L; Tian Y; Qian Z; Yang L
Cancer Sci; 2021 Jun; 112(6):2481-2492. PubMed ID: 33792132
[TBL] [Abstract][Full Text] [Related]
5. DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine.
Zhang R; Tang L; Tian Y; Ji X; Hu Q; Zhou B; Ding Z; Xu H; Yang L
J Control Release; 2020 Dec; 328():210-221. PubMed ID: 32860927
[TBL] [Abstract][Full Text] [Related]
6. Triptolide decreases tumor-associated macrophages infiltration and M2 polarization to remodel colon cancer immune microenvironment via inhibiting tumor-derived CXCL12.
Jiang X; Cao G; Gao G; Wang W; Zhao J; Gao C
J Cell Physiol; 2021 Jan; 236(1):193-204. PubMed ID: 32495392
[TBL] [Abstract][Full Text] [Related]
7. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
9. Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
Esser AK; Ross MH; Fontana F; Su X; Gabay A; Fox GC; Xu Y; Xiang J; Schmieder AH; Yang X; Cui G; Scott M; Achilefu S; Chauhan J; Fletcher S; Lanza GM; Weilbaecher KN
Theranostics; 2020; 10(17):7510-7526. PubMed ID: 32685002
[TBL] [Abstract][Full Text] [Related]
10. Novel Self-Assembled Micelles Based on Cholesterol-Modified Antimicrobial Peptide (DP7) for Safe and Effective Systemic Administration in Animal Models of Bacterial Infection.
Zhang R; Wu F; Wu L; Tian Y; Zhou B; Zhang X; Huang R; Yu C; He G; Yang L
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201818
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection.
Huang Z; Gan J; Long Z; Guo G; Shi X; Wang C; Zang Y; Ding Z; Chen J; Zhang J; Dong L
Biomaterials; 2016 Jun; 90():72-84. PubMed ID: 26994345
[TBL] [Abstract][Full Text] [Related]
12. Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer.
Sun Y; Liu L; Zhou L; Yu S; Lan Y; Liang Q; Liu J; Cao A; Liu Y
ACS Appl Mater Interfaces; 2020 Oct; 12(41):45873-45890. PubMed ID: 32924511
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene.
Yang J; Zhang Z; Chen C; Liu Y; Si Q; Chuang TH; Li N; Gomez-Cabrero A; Reisfeld RA; Xiang R; Luo Y
Oncogene; 2014 Jun; 33(23):3014-23. PubMed ID: 23831570
[TBL] [Abstract][Full Text] [Related]
14. Targeted Delivery of miRNA 155 to Tumor Associated Macrophages for Tumor Immunotherapy.
Zang X; Zhang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D
Mol Pharm; 2019 Apr; 16(4):1714-1722. PubMed ID: 30860846
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
16. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors.
Choo YW; Kang M; Kim HY; Han J; Kang S; Lee JR; Jeong GJ; Kwon SP; Song SY; Go S; Jung M; Hong J; Kim BS
ACS Nano; 2018 Sep; 12(9):8977-8993. PubMed ID: 30133260
[TBL] [Abstract][Full Text] [Related]
17. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
18. Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression.
Xing Y; Ruan G; Ni H; Qin H; Chen S; Gu X; Shang J; Zhou Y; Tao X; Zheng L
Front Immunol; 2021; 12():624725. PubMed ID: 34084160
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Targeting Anti-MicroRNA-155 Delivery Based on Biodegradable Poly(ester amine) and Hyaluronic Acid Shielding for Lung Cancer Therapy.
Yang Y; Jia Y; Xiao Y; Hao Y; Zhang L; Chen X; He J; Zhao Y; Qian Z
Chemphyschem; 2018 Aug; 19(16):2058-2069. PubMed ID: 29488305
[TBL] [Abstract][Full Text] [Related]
20. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
